Recombinant interleukin-2 in lepromatous leprosy lesions: Immunological and microbiological consequences

Clinical and Experimental Dermatology

Volumn 22, Issue 3, 1997, Pages 134-140

  Villahermosa, L G ^a   Abalos, R M ^a   Walsh, D S ^b,c   Fajardo, T T ^a   Walsh, G P ^a  

^a Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c APACHE POINT OBSERVATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; RECOMBINANT INTERLEUKIN 2; RIFAMPICIN;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; EPITHELIOID CELL; ERYTHEMA; FEMALE; HELPER CELL; HUMAN; HUMAN TISSUE; INJECTION SITE; INTRADERMAL DRUG ADMINISTRATION; LANGERHANS CELL; LEPROMATOUS LEPROSY; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN GRANULOMA;

ADOLESCENT; ADULT; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; MALE; RECOMBINANT PROTEINS;

EID: 0030752674     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.1997.tb01041.x     Document Type: Article

References (25)

1. Cohn ZA, Kaplan G. Hansen's disease, cell mediated immunity, and recombinant lymphokines. J Inf Dis 1991; 163: 1195-200.
2. Kaplan G, Cohn ZA. Leprosy and cell-mediated immunity. Curr Opin Immunol 1991; 3: 91-6.
3. Kaplan G, Britton WJ, Hancock GE et al. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J Exp Med 1991; 173: 993-1006.
4. Molloy A, Gaudernack G, Levis WR et al. Suppression of T-cell proliferation by Mycobacterium leprae and its products: role of lipopolysaccharide. Proc Natl Acad Sci USA 1990; 87: 973-7.
5. Kaplan G, Sampaio EP, Walsh GP et al. Influence of Mycobacterium leprae and its soluble products on the cutaneous responsiveness of leprosy patients to antigen and recombinant interleukin-2. Proc Natl Acad Sci USA 1989; 86: 6269-73.
6. Kaplan G, Laal S, Sheftel G et al. The nature and kinetics of a delayed immune response to purified protein derivative to tuberculin in the skin of lepromatous leprosy patients. J Exp Med 1988; 168: 1811-24.
7. Kaplan G, Sheftel G, Job CK et al. Efficacy of a cell-mediated reaction to the purified protein derivative of tuberculin in the disposal of Mycobacterium leprae from human skin. Proc Natl Acad Sci USA 1988; 85: 5210-5214.
8. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169-76.
9. Converse P, Ottenhoff TH, Teklemariam SW et al. Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Scand J Immunol 1990; 32: 83-91.
10. Kaplan G, Kiessling R, Teklemariam SW et al. The reconstitution of cell mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med 1989; 169: 893-907.
11. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five group system. Int J Lepr 1966; 34: 255-73.
12. World Health Organisation. Manual of Basic Techniques for a Health Laboratory. Geneva: World Health Organisation, 1980.
13. Walsh DS, Guido LS, Fajardo TT. The treatment of leprosy: a brief history and current chemotherapeutic guidelines. Med Sci Res 1989; 194: 271-3.
14. World Health Organisation Report of Study Group: Chemotherapy of leprosy for control programmes. WHO Tech Rep Ser 1982; 675: 1-33.
15. Ridley DS. A logarithmic index of bacilli in biopsies, 1. Method. Int J Lepr 1967; 35: 184-6.
16. Ridley DS. A logarithmic index of bacilli in biopsies, 2. Evaluation. Int J Lepr 1967; 35: 187-93.
17. Saloga J, Leung DY, Reardon C et al. Cutaneous exposure to the superantigen staphylococcal enterotoxin B elicits a T-cell-dependent inflammatory response. J Inv Dermatol 1996; 106: 982-8.
18. Yamamura M, Uyemura K, Deans RJ et al. Defining the protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254: 277-9.
19. Sieling PA, Modlin RL. Cytokine patterns at the site of mycobacterial infection. Immunobiol 1994; 191: 378-87.
20. Burmudez LE, Kaplan G. Recombinant cytokines for controlling mycobacterial infections. Trends Microbiol 1995; 3: 22-7.
21. Kaplan G, Nusrat A, Sarno EN et al. Cellular responses to the intradermal injection of recombinant human γ-interferon in lepromatous leprosy patients. Am J Pathol 1987; 128: 345-53.
22. Sampaio EP, Moreira AL, Sarno EN et al. Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175: 1729-37.
23. Kaplan G, Witmer MD, Nath I et al. Influence of delayed immune reactions on human epidermal keratinocytes. Proc Natl Acad Sci USA 1986; 83: 3469-73.
24. Jolliffe DS. Leprosy reactional states and their treatment. Br J Dermatol 1977; 97: 345-52.
25. Cree IA, Smith WC, Rees RJ, Beck JS. The influence of antimycobacterial chemotherapy on delayed hypersensitivity skin-test reaction in leprosy patients. Lepr Rev 1988; 59: 145-51.